Copyright Reports & Markets. All rights reserved.

Global Pet Cancer Therapeutics Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Pet Cancer Therapeutics

      • 1.1 Definition of Pet Cancer Therapeutics
      • 1.2 Pet Cancer Therapeutics Segment by Type
        • 1.2.1 Global Pet Cancer Therapeutics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Chemotherapy
        • 1.2.3 Targeted Therapy
        • 1.2.4 Combination Therapy
        • 1.2.5 Immunotherapy
      • 1.3 Pet Cancer Therapeutics Segment by Applications
        • 1.3.1 Global Pet Cancer Therapeutics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Lymphoma
        • 1.3.3 Mast Cell Cancer
        • 1.3.4 Melanoma
        • 1.3.5 Mammary
        • 1.3.6 Squamous Cell Cancer
        • 1.3.7 Others
      • 1.4 Global Pet Cancer Therapeutics Overall Market
        • 1.4.1 Global Pet Cancer Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Pet Cancer Therapeutics Production (2014-2025)
        • 1.4.3 North America Pet Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.4 Europe Pet Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.5 China Pet Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.6 Japan Pet Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Pet Cancer Therapeutics Status and Prospect (2014-2025)
        • 1.4.8 India Pet Cancer Therapeutics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Pet Cancer Therapeutics
      • 2.3 Manufacturing Process Analysis of Pet Cancer Therapeutics
      • 2.4 Industry Chain Structure of Pet Cancer Therapeutics

      3 Development and Manufacturing Plants Analysis of Pet Cancer Therapeutics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Pet Cancer Therapeutics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Pet Cancer Therapeutics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Pet Cancer Therapeutics Production and Capacity Analysis
      • 4.2 Pet Cancer Therapeutics Revenue Analysis
      • 4.3 Pet Cancer Therapeutics Price Analysis
      • 4.4 Market Concentration Degree

      5 Pet Cancer Therapeutics Regional Market Analysis

      • 5.1 Pet Cancer Therapeutics Production by Regions
        • 5.1.1 Global Pet Cancer Therapeutics Production by Regions
        • 5.1.2 Global Pet Cancer Therapeutics Revenue by Regions
      • 5.2 Pet Cancer Therapeutics Consumption by Regions
      • 5.3 North America Pet Cancer Therapeutics Market Analysis
        • 5.3.1 North America Pet Cancer Therapeutics Production
        • 5.3.2 North America Pet Cancer Therapeutics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Pet Cancer Therapeutics Import and Export
      • 5.4 Europe Pet Cancer Therapeutics Market Analysis
        • 5.4.1 Europe Pet Cancer Therapeutics Production
        • 5.4.2 Europe Pet Cancer Therapeutics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Pet Cancer Therapeutics Import and Export
      • 5.5 China Pet Cancer Therapeutics Market Analysis
        • 5.5.1 China Pet Cancer Therapeutics Production
        • 5.5.2 China Pet Cancer Therapeutics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Pet Cancer Therapeutics Import and Export
      • 5.6 Japan Pet Cancer Therapeutics Market Analysis
        • 5.6.1 Japan Pet Cancer Therapeutics Production
        • 5.6.2 Japan Pet Cancer Therapeutics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Pet Cancer Therapeutics Import and Export
      • 5.7 Southeast Asia Pet Cancer Therapeutics Market Analysis
        • 5.7.1 Southeast Asia Pet Cancer Therapeutics Production
        • 5.7.2 Southeast Asia Pet Cancer Therapeutics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Pet Cancer Therapeutics Import and Export
      • 5.8 India Pet Cancer Therapeutics Market Analysis
        • 5.8.1 India Pet Cancer Therapeutics Production
        • 5.8.2 India Pet Cancer Therapeutics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Pet Cancer Therapeutics Import and Export

      6 Pet Cancer Therapeutics Segment Market Analysis (by Type)

      • 6.1 Global Pet Cancer Therapeutics Production by Type
      • 6.2 Global Pet Cancer Therapeutics Revenue by Type
      • 6.3 Pet Cancer Therapeutics Price by Type

      7 Pet Cancer Therapeutics Segment Market Analysis (by Application)

      • 7.1 Global Pet Cancer Therapeutics Consumption by Application
      • 7.2 Global Pet Cancer Therapeutics Consumption Market Share by Application (2014-2019)

      8 Pet Cancer Therapeutics Major Manufacturers Analysis

      • 8.1 Aratana Therapeutics, Inc
        • 8.1.1 Aratana Therapeutics, Inc Pet Cancer Therapeutics Production Sites and Area Served
        • 8.1.2 Aratana Therapeutics, Inc Product Introduction, Application and Specification
        • 8.1.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 AB Science
        • 8.2.1 AB Science Pet Cancer Therapeutics Production Sites and Area Served
        • 8.2.2 AB Science Product Introduction, Application and Specification
        • 8.2.3 AB Science Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Boehringer Ingelheim International GmbH
        • 8.3.1 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Production Sites and Area Served
        • 8.3.2 Boehringer Ingelheim International GmbH Product Introduction, Application and Specification
        • 8.3.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Zenoaq
        • 8.4.1 Zenoaq Pet Cancer Therapeutics Production Sites and Area Served
        • 8.4.2 Zenoaq Product Introduction, Application and Specification
        • 8.4.3 Zenoaq Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Morphogenesis, Inc
        • 8.5.1 Morphogenesis, Inc Pet Cancer Therapeutics Production Sites and Area Served
        • 8.5.2 Morphogenesis, Inc Product Introduction, Application and Specification
        • 8.5.3 Morphogenesis, Inc Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 VetDC, Inc
        • 8.6.1 VetDC, Inc Pet Cancer Therapeutics Production Sites and Area Served
        • 8.6.2 VetDC, Inc Product Introduction, Application and Specification
        • 8.6.3 VetDC, Inc Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Karyopharm Therapeutics, Inc
        • 8.7.1 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Production Sites and Area Served
        • 8.7.2 Karyopharm Therapeutics, Inc Product Introduction, Application and Specification
        • 8.7.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Rhizen Pharmaceutical SA
        • 8.8.1 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Production Sites and Area Served
        • 8.8.2 Rhizen Pharmaceutical SA Product Introduction, Application and Specification
        • 8.8.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Regeneus Ltd.
        • 8.9.1 Regeneus Ltd. Pet Cancer Therapeutics Production Sites and Area Served
        • 8.9.2 Regeneus Ltd. Product Introduction, Application and Specification
        • 8.9.3 Regeneus Ltd. Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Oasmia Pharmaceuticals AB
        • 8.10.1 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Production Sites and Area Served
        • 8.10.2 Oasmia Pharmaceuticals AB Product Introduction, Application and Specification
        • 8.10.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Zoetis

      9 Development Trend of Analysis of Pet Cancer Therapeutics Market

      • 9.1 Global Pet Cancer Therapeutics Market Trend Analysis
        • 9.1.1 Global Pet Cancer Therapeutics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Pet Cancer Therapeutics Regional Market Trend
        • 9.2.1 North America Pet Cancer Therapeutics Forecast 2019-2025
        • 9.2.2 Europe Pet Cancer Therapeutics Forecast 2019-2025
        • 9.2.3 China Pet Cancer Therapeutics Forecast 2019-2025
        • 9.2.4 Japan Pet Cancer Therapeutics Forecast 2019-2025
        • 9.2.5 Southeast Asia Pet Cancer Therapeutics Forecast 2019-2025
        • 9.2.6 India Pet Cancer Therapeutics Forecast 2019-2025
      • 9.3 Pet Cancer Therapeutics Market Trend (Product Type)
      • 9.4 Pet Cancer Therapeutics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Pet Cancer Therapeutics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
        The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth.

        The global Pet Cancer Therapeutics market was valued at 180 million US$ in 2018 and will reach 330 million US$ by the end of 2025, growing at a CAGR of 7.7% during 2019-2025.
        This report focuses on Pet Cancer Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pet Cancer Therapeutics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Pet Cancer Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Pet Cancer Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Aratana Therapeutics, Inc
        AB Science
        Boehringer Ingelheim International GmbH
        Zenoaq
        Morphogenesis, Inc
        VetDC, Inc
        Karyopharm Therapeutics, Inc
        Rhizen Pharmaceutical SA
        Regeneus Ltd.
        Oasmia Pharmaceuticals AB
        Zoetis

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Chemotherapy
        Targeted Therapy
        Combination Therapy
        Immunotherapy

        Segment by Application
        Lymphoma
        Mast Cell Cancer
        Melanoma
        Mammary
        Squamous Cell Cancer
        Others

        Buy now